Circulating microRNA‐1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma
Makoto Chuma(Yokohama City University Medical Center), Naoya Sakamoto(Chibaken Saiseikai Narashino Hospital), Katsuaki Ogushi(Yokohama City University Medical Center), Satoshi Moriya(Yokohama City University Medical Center), Hidenori Toyoda(Ogaki Municipal Hospital), Kazushi Numata(Yokohama City University Medical Center), Takashi Kumada(Gifu Kyoritsu University), Masaaki Kondo(Yokohama City University Medical Center), Chikara Kunisaki(Yokohama City University), Atsuyuki Maeda(Ogaki Municipal Hospital), Hiroyuki Fukuda(Yokohama City University Medical Center), Koji Hara(Yokohama City University Medical Center), Toshifumi Tada(Himeji Red Cross Hospital), Hideki Yokoo(Hokkaido University), Koji Ogawa(The Japanese Society of Gastroenterological Surgery), Yoshihiro Matsuno(Hokkaido University Hospital), Akito Nozaki(Yokohama City University Medical Center), Toshiya Kamiyama(Hokkaido University), Akinobu Taketomi(Hokkaido University), Keiichi Yazawa(Yokohama City University Medical Center), Kazuhisa Takeda(Tohoku University), Katsuaki Tanaka(Yokohama City University Medical Center), Yuji Kaneoka(Ogaki Municipal Hospital), Juntaro Matsuzaki(Keio University), Yoshimasa Saito(Royal Netherlands Academy of Arts and Sciences), Shin Maeda(University of Tokyo Hospital)
Cited by 43
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573